Rubén Francés

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/50409/publications.pdf

Version: 2024-02-01

110 papers

4,551 citations

36 h-index 62 g-index

115 all docs

115 docs citations

115 times ranked

4875 citing authors

#	Article	IF	CITATIONS
1	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. Frontiers in Medicine, 2022, 9, 823900.	2.6	4
2	Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn's disease. Biomedicine and Pharmacotherapy, 2022, 147, 112653.	5.6	5
3	Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy. Cell Death and Disease, 2022, 13, 143.	6.3	16
4	Absent in Melanoma 2 (AIM2) Regulates the Stability of Regulatory T Cells. International Journal of Molecular Sciences, 2022, 23, 2230.	4.1	10
5	Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH). GastroenterologAa Y HepatologAa, 2022, 45, 724-734.	0.5	3
6	Paneth Cells Regulate Lymphangiogenesis under Control of Microbial Signals during Experimental Portal Hypertension. Biomedicines, 2022, 10, 1503.	3.2	4
7	<i>Bacteroides uniformis</i> combined with fiber amplifies metabolic and immune benefits in obese mice. Gut Microbes, 2021, 13, 1-20.	9.8	81
8	Dysbiotic microbiota interactions in Crohn's disease. Gut Microbes, 2021, 13, 1949096.	9.8	38
9	Role of liver sinusoidal endothelial cells in liver diseases. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 411-431.	17.8	150
10	Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis. American Journal of Gastroenterology, 2021, 116, 1238-1247.	0.4	12
11	Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, 15, 1846-1851.	1.3	39
12	Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Scientific Reports, 2021, 11, 8593.	3.3	15
13	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsyâ€proven nonalcoholic fatty liver disease subjects. Liver International, 2021, 41, 2076-2086.	3.9	13
14	Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. International Journal of Environmental Research and Public Health, 2021, 18, 5227.	2.6	109
15	Endocrine disruption in Crohn's disease: Bisphenol A enhances systemic inflammatory response in patients with gut barrier translocation of dysbiotic microbiota products. FASEB Journal, 2021, 35, e21697.	0.5	17
16	Bacterial Translocation as Inflammatory Driver in Crohn's Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 703310.	3.7	25
17	Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease. Frontiers in Pharmacology, 2021, 12, 795272.	3.5	1
18	Identification of bacterial DNA in the peripheral blood of patients with active hidradenitis suppurativa. Archives of Dermatological Research, 2020, 312, 159-163.	1.9	11

#	Article	lF	CITATIONS
19	Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2020, 18, 216-225.e5.	4.4	104
20	Acetaminophenâ€Induced Liver Damage in Hepatic Steatosis. Clinical Pharmacology and Therapeutics, 2020, 107, 1068-1081.	4.7	22
21	Functionality of beta-adrenergic receptors in patients with cirrhosis treated chronically with non-selective beta-blockers. Hepatology International, 2020, 14, 858-868.	4.2	3
22	Liver Sinusoidal Endothelial Cells Contribute to Hepatic Antigen-Presenting Cell Function and Th17 Expansion in Cirrhosis. Cells, 2020, 9, 1227.	4.1	13
23	Bacterial antigen translocation and age as BMIâ€independent contributing factors on systemic inflammation in NAFLD patients. Liver International, 2020, 40, 2182-2193.	3.9	14
24	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. Journal of Hepatology, 2020, 73, 17-25.	3.7	59
25	Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin. Clinical and Translational Gastroenterology, 2020, 11, e00143.	2.5	1
26	Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of B. pseudocatenulatum CECT 7765. European Journal of Nutrition, 2019, 58, 1647-1658.	3.9	13
27	Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB Journal, 2019, 33, 11595-11605.	0.5	68
28	FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. Journal of Hepatology, 2019, 71, 1126-1140.	3.7	153
29	Nonalcoholic fatty liver disease puts patients with psoriasis at greater cardiovascular risk. Australasian Journal of Dermatology, 2019, 60, e304-e310.	0.7	9
30	Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. , 2019, 10, 684.		30
31	Editorial: The IL-20 Cytokines and Related Family Members in Immunity and Diseases. Frontiers in Immunology, 2019, 10, 1976.	4.8	3
32	Bacterial DNA translocation contributes to systemic inflammation and to minor changes in the clinical outcome of liver transplantation. Scientific Reports, 2019, 9, 835.	3.3	16
33	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2019, 25, 1357-1366.	1.9	5
34	Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver International, 2018, 38, 295-302.	3.9	12
35	Impact of circulating bacterial DNA in long-term glucose homeostasis in non-diabetic patients with HIV infection: cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 313-318.	2.9	5
36	Regulatory T Cells Restrict Permeability to Bacterial Antigen Translocation and Preserve Shortâ€Chain Fatty Acids in Experimental Cirrhosis. Hepatology Communications, 2018, 2, 1610-1623.	4.3	15

#	Article	IF	CITATIONS
37	The effects of metabolic status on nonâ€alcoholic fatty liver diseaseâ€related outcomes, beyond the presence of obesity. Alimentary Pharmacology and Therapeutics, 2018, 48, 1260-1270.	3.7	70
38	Effects of aging on liver microcirculatory function and sinusoidal phenotype. Aging Cell, 2018, 17, e12829.	6.7	92
39	Treatment with nonâ€selective betaâ€blockers affects the systemic inflammatory response to bacterial <scp>DNA</scp> in patients with cirrhosis. Liver International, 2018, 38, 2219-2227.	3.9	17
40	The Interleukin-20 Cytokine Family in Liver Disease. Frontiers in Immunology, 2018, 9, 1155.	4.8	26
41	AIM2 deficiency reduces the development of hepatocellular carcinoma in mice. International Journal of Cancer, 2018, 143, 2997-3007.	5.1	30
42	Toll-like receptor polymorphisms compromise the inflammatory response against bacterial antigen translocation in cirrhosis. Scientific Reports, 2017, 7, 46425.	3.3	24
43	The expression and activation of the AIM2 inflammasome correlates with inflammation and disease severity in patients with acute pancreatitis. Pancreatology, 2017, 17, 364-371.	1.1	18
44	IL26 modulates cytokine response and anti-TNF consumption in Crohn's disease patients with bacterial DNA. Journal of Molecular Medicine, 2017, 95, 1227-1236.	3.9	9
45	Lactulose reduces bacterial <scp>DNA</scp> translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver International, 2017, 37, 212-223.	3.9	28
46	Selective intestinal decontamination with norfloxacin enhances a regulatory T cellâ€mediated inflammatory control mechanism in cirrhosis. Liver International, 2016, 36, 1811-1820.	3.9	12
47	Microbiome and bacterial translocation in cirrhosis. GastroenterologÃa Y HepatologÃa (English) Tj ETQq1 1 0.78	34314 rgB ⁻	T /Qverlock 1
48	Grade of soluble inflammatory response is mainly affected by circulating bacterial <scp>DNA</scp> concentrations in cirrhosis. Liver International, 2016, 36, 1473-1480.	3.9	11
49	Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis. European Journal of Nutrition, 2016, 55, 197-206.	3.9	23
50	Microbioma y traslocación bacteriana en la cirrosis. GastroenterologÃa Y HepatologÃa, 2016, 39, 687-696.	0.5	16
51	Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. American Journal of Gastroenterology, 2016, 111, 529-540.	0.4	34
52	Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis. Journal of Hepatology, 2016, 64, 135-145.	3.7	31
53	Dual-specificity phosphatase 6 regulates CD4+ T-cell functions and restrains spontaneous colitis in IL-10-deficient mice. Mucosal Immunology, 2015, 8, 505-515.	6.0	42
54	Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 147-154.	2.8	25

#	Article	IF	Citations
55	Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. Journal of Gastroenterology, 2015, 50, 758-768.	5.1	10
56	Identification of Bacterial DNA in the Peripheral Blood of Patients With Active Psoriasis. JAMA Dermatology, 2015, 151, 670.	4.1	81
57	Acute Effects of Dipyrone on Renal Function in Patients with Cirrhosis: A Randomized Controlled Trial. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 257-263.	2.5	8
58	Absent in melanoma 2 triggers a heightened inflammasome response in ascitic fluid macrophages of patients with cirrhosis. Journal of Hepatology, 2015, 62, 64-71.	3.7	41
59	Immunomodulating effects of antibiotics used in the prophylaxis of bacterial infections in advanced cirrhosis. World Journal of Gastroenterology, 2015, 21, 11493.	3.3	16
60	Protective effect of <i>Bifidobacterium pseudocatenulatum </i> <scp>CECT</scp> 7765 against induced bacterial antigen translocation in experimental cirrhosis. Liver International, 2014, 34, 850-858.	3.9	41
61	Oral probiotic <scp>VSL</scp> #3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver International, 2014, 34, 1504-1512.	3.9	61
62	Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut, 2014, 63, 272-280.	12.1	62
63	Bacterial DNA Translocation Holds Increased Insulin Resistance and Systemic Inflammatory Levels in Morbid Obese Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2575-2583.	3.6	34
64	Role of interleukin 10 in norfloxacin prevention of luminal free endotoxin translocation in mice with cirrhosis. Journal of Hepatology, 2014, 61, 799-808.	3.7	15
65	Gut microbiota-related complications in cirrhosis. World Journal of Gastroenterology, 2014, 20, 15624.	3.3	46
66	Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver International, 2013, 33, 31-39.	3.9	199
67	Low-Level HIV Viremia Is Associated With Microbial Translocation and Inflammation. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 129-134.	2.1	58
68	Role of <scp>MAP</scp> Kinases and <scp>PI</scp> 3Kâ€Akt on the cytokine inflammatory profile of peritoneal macrophages from the ascites of cirrhotic patients. Liver International, 2013, 33, 552-560.	3.9	23
69	Modulation of Inflammatory Response in a Cirrhotic Rat Model with Induced Bacterial Peritonitis. PLoS ONE, 2013, 8, e59692.	2.5	3
70	Intensified Anti-TNF-Alpha Therapy and Bacterial-DNA Translocation in Patients With Mutated NOD2/ATG16L1-Combined Genotypes. Inflammatory Bowel Diseases, 2012, 18, S60.	1.9	0
71	Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis. Hepatology, 2012, 56, 1861-1869.	7.3	56
72	The peritoneal macrophage inflammatory profile in cirrhosis depends on the alcoholic or hepatitis C viral etiology and is related to ERK phosphorylation. BMC Immunology, 2012, 13, 42.	2.2	25

#	Article	IF	CITATIONS
73	Beta-Adrenergic Receptor 1 Selective Antagonism Inhibits Norepinephrine-Mediated TNF-Alpha Downregulation in Experimental Liver Cirrhosis. PLoS ONE, 2012, 7, e43371.	2.5	12
74	Evidence of neutrophil functional defect despite inflammation in stable cirrhosis. Journal of Hepatology, 2011, 55, 574-581.	3.7	154
75	A CD25â^ Positive Population of Activated B1 Cells Expresses LIFR and Responds to LIF. Frontiers in Immunology, 2011, 2, 6.	4.8	16
76	Gut Microbiota Dysbiosis Is Associated with Inflammation and Bacterial Translocation in Mice with CCl4-Induced Fibrosis. PLoS ONE, 2011, 6, e23037.	2.5	111
77	Peritoneal macrophage priming in cirrhosis is related to ERK phosphorylation and ILâ \in 6 secretion. European Journal of Clinical Investigation, 2011, 41, 8-15.	3.4	21
78	Interleukin-10-mediated heme oxygenase 1-induced underlying mechanism in inflammatory down-regulation by norfloxacin in cirrhosis. Hepatology, 2011, 53, 935-944.	7.3	29
79	Antimicrobial peptide response to blood translocation of bacterial DNA in Crohnʽ disease is affected by NOD2/CARD15 genotype. Inflammatory Bowel Diseases, 2011, 17, 1641-1650.	1.9	44
80	Proteomic evidence of bacterial peptide translocation in afebrile patients with cirrhosis and ascites. Journal of Molecular Medicine, 2010, 88, 487-495.	3.9	10
81	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology, 2010, 52, 2044-2052.	7.3	180
82	Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis. Hepatology, 2010, 52, 2086-2095.	7.3	41
83	The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports. Alimentary Pharmacology and Therapeutics, 2010, 31, 1337-1345.	3.7	17
84	639 Bacterial DNA Modulates Human Beta-Defensin 2 Expression in Neutrophils of Wild-Type NOD-2/CARD15 Patients With Crohn's Disease. Gastroenterology, 2010, 138, S-84.	1.3	0
85	Reply:. Hepatology, 2009, 49, 1393-1394.	7.3	0
86	Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2009, 15, 508-514.	1.9	46
87	Causality assessment of liver injury after chronic oral amiodarone intake. Pharmacoepidemiology and Drug Safety, 2009, 18, 291-300.	1.9	10
88	Norfloxacin Modulates the Inflammatory Response and Directly Affects Neutrophils in Patients With Decompensated Cirrhosis. Gastroenterology, 2009, 137, 1669-1679.e1.	1.3	36
89	Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology, 2008, 47, 978-985.	7.3	152
90	Serum and ascitic fluid bacterial DNA: A new independent prognostic factor in noninfected patients with cirrhosis. Hepatology, 2008, 48, 1924-1931.	7.3	141

#	Article	IF	Citations
91	Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. Journal of Hepatology, 2008, 48, 61-67.	3.7	61
92	Bacterial DNA translocation in patients with cirrhosis: Reply. Journal of Hepatology, 2008, 49, 146-147.	3.7	0
93	Bacterial translocation is downregulated by anti-TNF-α monoclonal antibody administration in rats with cirrhosis and ascites. Journal of Hepatology, 2007, 46, 797-803.	3.7	48
94	Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clinical and Experimental Immunology, 2007, 150, 230-237.	2.6	32
95	Bacterial DNA Induces the Complement System Activation in Serum and Ascitic Fluid from Patients with Advanced Cirrhosis. Journal of Clinical Immunology, 2007, 27, 438-444.	3.8	36
96	B-1 cells express transgelin 2: Unexpected lymphocyte expression of a smooth muscle protein identified by proteomic analysis of peritoneal B-1 cells. Molecular Immunology, 2006, 43, 2124-2129.	2.2	21
97	The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology, 2006, 44, 633-639.	7.3	88
98	Extreme skewing of annexin II and S100A6 expression identified by proteomic analysis of peritoneal B-1 cells. International Immunology, 2006, 19, 59-65.	4.0	12
99	Intracellular cytokine expression in peritoneal monocyte/macrophages obtained from patients with cirrhosis and presence of bacterial DNA. European Journal of Gastroenterology and Hepatology, 2005, 17, 45-51.	1.6	34
100	Cutting Edge: B-1 Cells Are Deficient in Lck: Defective B Cell Receptor Signal Transduction in B-1 Cells Occurs in the Absence of Elevated Lck Expression. Journal of Immunology, 2005, 175, 27-31.	0.8	21
101	Norfloxacin decreases bacterial adherence of quinolone-resistant strains of Escherichia coli isolated from patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2005, 21, 701-707.	3.7	6
102	Detection and identification of bacterial DNA in serum from patients with acute pancreatitis. Gut, 2005, 54, 1293-1297.	12.1	48
103	Cutting Edge: Spontaneously Ig-Secreting B-1 Cells Violate the Accepted Paradigm for Expression of Differentiation-Associated Transcription Factors. Journal of Immunology, 2005, 174, 3173-3177.	0.8	96
104	Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status. Alimentary Pharmacology and Therapeutics, 2004, 20, 29-36.	3.7	36
105	A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites. Hepatology, 2004, 39, 484-491.	7. 3	132
106	Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut, 2004, 53, 860-864.	12.1	116
107	Nitric oxide in ascitic fluid is an independent predictor of the development of renal impairment in patients with cirrhosis and spontaneous bacterial peritonitis. European Journal of Gastroenterology and Hepatology, 2004, 16, 571-577.	1.6	41
108	A Unique Transcriptional Profile for Spontaneously Immunoglobulin Secreting B-1 Cells Blood, 2004, 104, 3236-3236.	1.4	0

Rubén Francés

#	Article	lF	CITATIONS
109	Nitric oxide in patients with cirrhosis and bacterial infections. Metabolic Brain Disease, 2002, 17, 303-309.	2.9	15
110	Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology, 2002, 36, 135-141.	7.3	264